Restoring Human Connection Through Neuroaffective Medicine

Rates of social disorders are rising sharply as social media, constant connectivity, and accelerated relationship dynamics change how humans bond. People are becoming more isolated, anxious, and emotionally volatile than ever before.

These disorders have significant personal, societal, and economic costs, yet they remain largely overlooked by the pharmaceutical industry.

We repurpose proven molecules to unlock overlooked therapeutic potential, guided by three principles:

Untapped biological opportunity: The number of receptor targets explored in pharmacology is increasing rapidly, yet only a small fraction of compounds make it to approval.

Misaligned trials: Many compounds are abandoned not because they lack efficacy, but because they were tested for the wrong indications.

Mechanistic Blindspots: Existing drug development follows predefined disease labels rather than systematically targeting the underlying symptom clusters and neurobiological pathways that drive those symptoms.

This approach allows us to bring safe, proven compounds to new uses faster, at lower cost, and with higher likelihood of success.

In biopharma, the agility and inventive edge of an early-stage startup almost never survive the transition into a large corporation. Growth usually brings layers of management, slower decisions, and rising costs that smother the very innovation that made the company successful.

The industry operates on the belief that developing medicines requires slow timelines and heavy infrastructure.

We are building a working demonstration of the opposite. Our model is lean, efficient, and deliberately contrarian to the way drug companies have always been run.